血液生物标志物pTau217、GFAP、NfL与Aβ比值评估黑人与白人老年人认知下降及痴呆风险
本研究在社区队列中测量431名黑人和583名白人无痴呆老年人的血浆神经丝轻链、胶质纤维酸性蛋白、淀粉样蛋白β42/40比值和磷酸化tau217,随访长达15年。结果显示pTau217与痴呆风险和认知下降高度相关,且黑人中pTau217与整体认知和语义记忆下降的关联更强,但生物标志物与认知下降的关联在黑人和白人参与者中总体相似。
要点
- pTau217对3年痴呆的判别能力良好,黑人AUC 0.81,白人AUC 0.77,优于年龄和MMSE。
- 黑人中pTau217与整体认知下降(β=-0.03,p=0.018)和语义记忆下降(β=-0.068,p<0.001)的关联更强。
- 生物标志物水平在黑人和白人之间相似,且与多种共病(尤其肾功能障碍和BMI)相关。
核心结论
- pTau217与痴呆风险和认知下降高度相关,且在黑人中与整体认知和语义记忆下降的关联更强。
- 生物标志物与认知下降的关联在黑人和白人参与者中总体相似。
研究设计与样本
- 基于社区队列的纵向研究,纳入431名黑人和583名白人无痴呆老年人,平均年龄分别为77岁和80岁,男性分别占17%和21%。
- 每年评估认知和痴呆,随访长达15年,并采用马氏距离平衡1:1匹配生成366:366样本以比较种族差异。
主要发现
- pTau217与整体认知和领域认知下降相关(所有p<0.001)。
- 黑人中pTau217与整体认知下降(β=-0.03,SE=0.012,p=0.018)和语义记忆下降(β=-0.068,SE=0.016,p<0.001)的关联更强。
- pTau217判别3年痴呆的AUC在黑人中为0.81(95%CI 0.74-0.89),白人中为0.77(95%CI 0.71-0.83)。
- 年龄判别3年痴呆的AUC在黑人中为0.69(95%CI 0.58-0.79),白人中为0.68(95%CI 0.62-0.75)。
- MMSE判别3年痴呆的AUC在黑人中为0.81(95%CI 0.74-0.89),白人中为0.72(95%CI 0.65-0.80)。
关键数值与推荐
- pTau217判别3年痴呆的AUC:黑人0.81(95%CI 0.74-0.89),白人0.77(95%CI 0.71-0.83)。
- 年龄判别3年痴呆的AUC:黑人0.69(95%CI 0.58-0.79),白人0.68(95%CI 0.62-0.75)。
- MMSE判别3年痴呆的AUC:黑人0.81(95%CI 0.74-0.89),白人0.72(95%CI 0.65-0.80)。
- 黑人中pTau217与整体认知下降的β=-0.03(SE=0.012,p=0.018),与语义记忆下降的β=-0.068(SE=0.016,p<0.001)。
- 男性GFAP低于女性(所有p<0.001)。
临床怎么用
- pTau217可作为评估老年人痴呆风险的血液生物标志物,其判别能力优于年龄和MMSE。
- 在黑人老年人中,pTau217可能有助于识别整体认知和语义记忆下降风险较高的个体。
- 解读生物标志物时需考虑肾功能、BMI等共病因素,因其与生物标志物水平相关。
局限性
- 研究结果的外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Alzheimer disease blood-based biomarkers are a cost-effective method for early detection. Few studies provide long-term follow-up of cognition in Black participants. We assessed biomarker association with cognitive decline and dementia risk in Black and White participants. METHODS: Plasma biomarkers (neurofilament light chain, glial fibrillary acidic protein [GFAP], amyloid-β 42/40 ratio, phosphorylated tau at threonine 217 [pTau217]) were measured in participants from a community-based Chicago cohort without dementia at the time of blood draw. They were evaluated annually for up to 15 years for cognition and dementia. Data included medical history, blood tests (e.g., kidney function), Mini-Mental State Examination (MMSE) score, and APOEε4. Associations of biomarkers with comorbidities, cognitive decline, and risk of dementia were examined within racial groups. To examine racial differences, we repeated the analysis using a Mahalanobis-balanced 1:1 match on biological sex, age, education, Latino/non-Latino status, longitudinal data availability, and clinical status (hypertension, diabetes, glomerular filtration rate, body mass index [BMI], and heart disease). RESULTS: Biomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. Biomarker levels were similar across races. Within racial groups, the associations of biomarkers with multiple comorbidities (especially kidney dysfunction and BMI) remained after controlling for demographics, APOEε4 status, and dementia or death within 5 years. Men had lower GFAP than women (all p < 0.001). Within racial groups, pTau217 was associated with a decline in global cognition and domains (all p < 0.001), and between races, pTau217 was associated with a faster decline in global cognition (β = -0.03, SE = 0.012, p = 0.018) and semantic memory (β = -0.068, SE = 0.016, p < 0.001) in Black individuals. The discrimination of dementia by pTau217 (area under the curve [AUC]3-year, Black 0.81, 95% CI 0.74-0.89; AUC3-year, White 0.77, 95% CI 0.71-0.83) was good relative to age (AUC3-year, Black 0.69, 95% CI 0.58-0.79; AUC3-year, White 0.68, 95% CI 0.62-0.75) and MMSE score (AUC3-year, Black 0.81, 95% CI 0.74-0.89; AUC3-year, White 0.72, 95% CI 0.65-0.80). The discrimination by pTau217 did not improve when adding other biomarkers or MMSE score. DISCUSSION: pTau217 was highly associated with dementia risk and cognitive decline. The association of biomarkers with cognitive decline in Black and White participants was similar. Higher pTau217 was, however, associated with global and semantic memory decline in Black adults. Generalizability is a limitation.
引用
- Capuano AW, Bennett DA, Dage JL, et al. Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio. Neurology. 2025. PMID: 41151002. doi:10.1212/WNL.0000000000214317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。